Cracking the ageing code

Technological advancements are revolutionizing various aspects of our lives, from communication to work. Over the past two decades, scientists have gained a deeper understanding of the aging process and are exploring methods to slow its progression. Head of Investment Strategy at RBC Wealth Management, Frédérique Carrier, delves into some of the most promising developments and their potential financial implications.

While life expectancy has doubled over the past 150 years, the focus has shifted towards improving healthspan, the number of years spent in good health. Chronic diseases, such as heart disease, diabetes, and dementia, account for 16-20% of life spent in poor health. The global population aged 60 and above is projected to reach 2.1 billion by 2050, with China experiencing the most significant impact.

Two main hypotheses explain the aging process: developmental processes continuing to operate into adulthood or the body's reduced ability to repair itself. Regardless of the cause, aging is characterized by cellular changes, such as genetic mutations, shortened chromosome ends, tissue debris accumulation, stem cell exhaustion, and mitochondrial decline. Venki Ramakrishnan, a molecular biologist and Nobel Prize laureate, identifies three promising approaches: senolytics, stem cell regeneration, and telomerase reactivation.

Senolytics target senescent cells, which accumulate as we age and secrete inflammatory molecules that damage nearby tissues. Stem cell regeneration focuses on rejuvenating or reprogramming cells to regenerate tissues, while telomerase reactivation aims to prevent telomeres from shortening and stopping cell division. Although these methods show promise, widespread implementation could take several decades. In the meantime, investors may find opportunities in healthspan-expanding solutions.